As it turns out, select Wall Street analysts believe that these two stocks could gain at least 20% over the next year.

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

Buffett has taken a highly conservative approach to the stock market in recent years. However, he bought these three stocks ...

Beyond Meat's operating performance and corporate strategy have come into focus, which is bad news for investors.

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, Nov. 13: Skillsoft ...

Despite the broader stock market's strong performance over the past few years, there are pockets of value where investors can still find good deals. Here are five rock-solid dividend stocks trading at ...